TriNetX cohort study (547,993 matched adults, published in JAAD International, 2026): GLP1 users were 40 percent more likely to develop nonscarring hair loss, 64 percent more likely to develop pattern thinning, and 76 percent more likely to experience stress-related shedding
Hooshmand S, Balakrishnan A, Clark RM, et al
liraglutide, dulaglutide and semaglutide) show a beneficial impact on inflammation, hepatic steatosis, blood pressure, and endothelial function including cardioprotective effects and evidence of kidney protection [8]
This is in accordance with unpublished data from our prior study in vervet monkeys investigating the effects of the two GLP-1 RAs exenatide and liraglutide (Thomsen et al